-
1
-
-
84966192535
-
The histological structure of some human lung cancers and possible implications for radiotherapy
-
R.H. Thomlinson, L.H. Gray The histological structure of some human lung cancers and possible implications for radiotherapy Br J Cancer 9 1955 539 549
-
(1955)
Br J Cancer
, vol.9
, pp. 539-549
-
-
Thomlinson, R.H.1
Gray, L.H.2
-
2
-
-
0034176782
-
Exploiting the hypoxic cancer cell: Mechanisms and therapeutic strategies
-
J.M. Brown Exploiting the hypoxic cancer cell Mechanisms and therapeutic strategies Mol Med Today 6 2000 157 162
-
(2000)
Mol Med Today
, vol.6
, pp. 157-162
-
-
Brown, J.M.1
-
3
-
-
30544453202
-
Cancer: Principles and practice of oncology
-
V.T. De Vita S. Hellman S. Rosenberg Lippincott, Williams and Wilkins Philadelphia
-
P.P. Connell, M.K. Martel, S. Hellman Cancer Principles and practice of oncology V.T. De Vita S. Hellman S. Rosenberg Principles of cancer management Radiation therapy 2001 Lippincott, Williams and Wilkins Philadelphia 274 275
-
(2001)
Principles of Cancer Management: Radiation Therapy
, pp. 274-275
-
-
Connell, P.P.1
Martel, M.K.2
Hellman, S.3
-
4
-
-
0016587704
-
Selective radiosensitization of the hypoxic cells of mouse tumors with the nitroimidazoles metronidazole and Ro7-0582
-
J.M. Brown Selective radiosensitization of the hypoxic cells of mouse tumors with the nitroimidazoles metronidazole and Ro7-0582 Radiat Res 64 1975 633 647
-
(1975)
Radiat Res
, vol.64
, pp. 633-647
-
-
Brown, J.M.1
-
5
-
-
0017388874
-
Clinical testing of the radiosensitizer Ro 07-0582: Experience with multiple doses
-
S. Dische, M.I. Saunders, M.E. Lee Clinical testing of the radiosensitizer Ro 07-0582 Experience with multiple doses Br J Cancer 35 1977 567 579
-
(1977)
Br J Cancer
, vol.35
, pp. 567-579
-
-
Dische, S.1
Saunders, M.I.2
Lee, M.E.3
-
6
-
-
0021236301
-
Clinical trials of radiosensitizers: What should we expect?
-
J.M. Brown Clinical trials of radiosensitizers What should we expect? Int J Radiat Oncol Biol Phys 10 1984 425 429
-
(1984)
Int J Radiat Oncol Biol Phys
, vol.10
, pp. 425-429
-
-
Brown, J.M.1
-
7
-
-
0033405294
-
The hypoxic cell: A target for selective cancer therapy - Eighteenth Bruce F. Cain memorial award lecture
-
J.M. Brown The hypoxic cell A target for selective cancer therapy - Eighteenth Bruce F. Cain memorial award lecture Cancer Res 59 1999 5863 5870
-
(1999)
Cancer Res
, vol.59
, pp. 5863-5870
-
-
Brown, J.M.1
-
8
-
-
0001168282
-
Intranuclear metabolism of tirapazamine by matrix-associated reductases
-
Y.M. Delahoussaye, B.G. Wouters, J.E. Evans Intranuclear metabolism of tirapazamine by matrix-associated reductases [Abstract] Proc Am Assoc Cancer Res 38 1997 163
-
(1997)
Proc Am Assoc Cancer Res
, vol.38
, pp. 163
-
-
Delahoussaye, Y.M.1
Wouters, B.G.2
Evans, J.E.3
-
9
-
-
0025646401
-
Potentiation by the hypoxic cytotoxin SR 4233 of cell killing produced by fractionated irradiation of mouse tumors
-
J.M. Brown, M.J. Lemmon Potentiation by the hypoxic cytotoxin SR 4233 of cell killing produced by fractionated irradiation of mouse tumors Cancer Res 50 1990 7745 7749
-
(1990)
Cancer Res
, vol.50
, pp. 7745-7749
-
-
Brown, J.M.1
Lemmon, M.J.2
-
11
-
-
0026513038
-
Enhancement of alkylating agent activity by SR-4233 in the FSaIIC murine fibrosarcoma
-
S.A. Holden, B.A. Teicher, G. Ara Enhancement of alkylating agent activity by SR-4233 in the FSaIIC murine fibrosarcoma J Natl Cancer Inst 84 1992 187 193
-
(1992)
J Natl Cancer Inst
, vol.84
, pp. 187-193
-
-
Holden, S.A.1
Teicher, B.A.2
Ara, G.3
-
12
-
-
84965808588
-
Tumor-specific, schedule-dependent interaction between tirapazamine (SR-4233) and cisplatin
-
M.J. Dorie, J.M. Brown Tumor-specific, schedule-dependent interaction between tirapazamine (SR-4233) and cisplatin Cancer Res 53 1993 4633 4636
-
(1993)
Cancer Res
, vol.53
, pp. 4633-4636
-
-
Dorie, M.J.1
Brown, J.M.2
-
13
-
-
0035164690
-
An investigation of the molecular basis for the synergistic interaction of tirapazamine and cisplatin
-
Z. Goldberg, J. Evans, G. Birrell An investigation of the molecular basis for the synergistic interaction of tirapazamine and cisplatin Int J Radiat Oncol Biol Phys 49 2001 175 182
-
(2001)
Int J Radiat Oncol Biol Phys
, vol.49
, pp. 175-182
-
-
Goldberg, Z.1
Evans, J.2
Birrell, G.3
-
14
-
-
0036121220
-
Tirapazamine: Prototype for a novel class of therapeutic agents targeting tumor hypoxia
-
D.R. Gandara, P.N. Lara, Z. Goldberg Tirapazamine Prototype for a novel class of therapeutic agents targeting tumor hypoxia Semin Oncol 29 2002 102 109
-
(2002)
Semin Oncol
, vol.29
, pp. 102-109
-
-
Gandara, D.R.1
Lara, P.N.2
Goldberg, Z.3
-
15
-
-
0000719908
-
A phase I/II trial of the combination of tirapazamine and cisplatin in patients with non-small cell lung cancer
-
G.I. Rodriguez, M. Valdivieso, D.D. Von Hoff A phase I/II trial of the combination of tirapazamine and cisplatin in patients with non-small cell lung cancer [Abstract] Prox Am Soc Clin Oncol 15 1996 382a
-
(1996)
Prox Am Soc Clin Oncol
, vol.15
-
-
Rodriguez, G.I.1
Valdivieso, M.2
Von Hoff, D.D.3
-
16
-
-
0031734636
-
Tirapazamine with cisplatin in patients with advanced non-small cell lung cancer: A phase II study
-
J. Treat, E. Johnson, C. Langer Tirapazamine with cisplatin in patients with advanced non-small cell lung cancer A phase II study J Clin Oncol 16 1998 3524 3527
-
(1998)
J Clin Oncol
, vol.16
, pp. 3524-3527
-
-
Treat, J.1
Johnson, E.2
Langer, C.3
-
17
-
-
0034104328
-
Tirapazamine plus cisplatin versus cisplatin in advanced non-small cell lung cancer: A report of the international CATAPULT I study group
-
J. Von Pawel, R. Von Roemeling, U. Gatzemeier Tirapazamine plus cisplatin versus cisplatin in advanced non-small cell lung cancer A report of the international CATAPULT I study group J Clin Oncol 18 2000 1351 1359
-
(2000)
J Clin Oncol
, vol.18
, pp. 1351-1359
-
-
Von Pawel, J.1
Von Roemeling, R.2
Gatzemeier, U.3
-
18
-
-
0001803741
-
Comparison of tirazone (tirapazamine) and cisplatin versus etoposide and cisplatin in advanced non-small cell lung cancer: Final results of the international phase III CATAPULT trial. Proceedings of the International Association for the Study of Lung Cancer, 9th World Conference on Lung Cancer, Tokyo, Japan, September 2000
-
F. Sheperd, G. Koschel, J. Von Pawel Comparison of tirazone (tirapazamine) and cisplatin versus etoposide and cisplatin in advanced non-small cell lung cancer: Final results of the international phase III CATAPULT trial. Proceedings of the International Association for the Study of Lung Cancer, 9th World Conference on Lung Cancer, Tokyo, Japan, September 2000 [Abstract] Lung Cancer 28 Suppl 1 2000 28
-
(2000)
Lung Cancer
, vol.28
, Issue.1 SUPPL.
, pp. 28
-
-
Sheperd, F.1
Koschel, G.2
Von Pawel, J.3
-
19
-
-
3843152488
-
S0003: Paclitaxel/carboplatin (PC) v PC + tirapazamine (PCT) in advanced non-small cell lung cancer (NSCLC). a phase III southwest oncology group (SWOG) trial
-
S.K. Williamson, J.J. Crowley, P.N. Lara S0003: Paclitaxel/carboplatin (PC) v PC + tirapazamine (PCT) in advanced non-small cell lung cancer (NSCLC). A phase III southwest oncology group (SWOG) trial [Abstract] Proc Am Soc Clin Oncol 22 2003 622
-
(2003)
Proc Am Soc Clin Oncol
, vol.22
, pp. 622
-
-
Williamson, S.K.1
Crowley, J.J.2
Lara, P.N.3
-
20
-
-
0032935606
-
Phase I trial of the hypoxic cell cytotoxin tirapazamine with concurrent radiation therapy in the treatment of refractory solid tumors
-
L.N. Shulman, L. Buswell, N. Riese Phase I trial of the hypoxic cell cytotoxin tirapazamine with concurrent radiation therapy in the treatment of refractory solid tumors Int J Radiat Oncol Biol Phys 44 1999 349 353
-
(1999)
Int J Radiat Oncol Biol Phys
, vol.44
, pp. 349-353
-
-
Shulman, L.N.1
Buswell, L.2
Riese, N.3
-
21
-
-
0141887809
-
Randomized trial of tirapazamine/cisplatin/fluorouracil versus cisplatin/fluorouracil for organ preservation in advanced respectable head and neck cancer
-
H.A. Pinto, Q. Le, D. Terris Randomized trial of tirapazamine/cisplatin/ fluorouracil versus cisplatin/fluorouracil for organ preservation in advanced respectable head and neck cancer [Abstract] Pro Am Soc Clin Oncol 21 2002 227a
-
(2002)
Pro Am Soc Clin Oncol
, vol.21
-
-
Pinto, H.A.1
Le, Q.2
Terris, D.3
-
22
-
-
0035863303
-
Phase I trial of concurrent tirapazamine, cisplatin, and radiotherapy in patients with advanced head and neck cancer
-
D. Rischen, L. Peters, R. Hicks Phase I trial of concurrent tirapazamine, cisplatin, and radiotherapy in patients with advanced head and neck cancer J Clin Oncol 19 2001 535 542
-
(2001)
J Clin Oncol
, vol.19
, pp. 535-542
-
-
Rischen, D.1
Peters, L.2
Hicks, R.3
-
23
-
-
16644377045
-
Tirapazamine, cisplatin and radiation versus fluorouracil, cisplatin and radiation in patients with locally advanced head and neck cancer: A randomized phase II trial of the trans-tasman radiation oncology group (TROG 98.02)
-
D. Rischin, L. Peters, R. Fisher Tirapazamine, cisplatin and radiation versus fluorouracil, cisplatin and radiation in patients with locally advanced head and neck cancer A randomized phase II trial of the trans-tasman radiation oncology group (TROG 98.02) J Clin Oncol 23 2005 79 87
-
(2005)
J Clin Oncol
, vol.23
, pp. 79-87
-
-
Rischin, D.1
Peters, L.2
Fisher, R.3
-
24
-
-
0034306888
-
A phase I/II evaluation of tirapazamine administered intravenously concurrent with cisplatin and radiotherapy in women with locally advanced cervical cancer
-
P.S. Craighead, R. Pearcey, G. Stuart A phase I/II evaluation of tirapazamine administered intravenously concurrent with cisplatin and radiotherapy in women with locally advanced cervical cancer Int J Radiat Oncol Biol Phys 48 2000 791 795
-
(2000)
Int J Radiat Oncol Biol Phys
, vol.48
, pp. 791-795
-
-
Craighead, P.S.1
Pearcey, R.2
Stuart, G.3
-
26
-
-
4143091521
-
Phase I study of tirapazamine plus cisplatin/etoposide and concurrent thoracic radiotherapy in limited-stage small cell lung cancer (S0004): A Southwest Oncology Group study
-
Q.T. Le, J. McCoy, S. Williamson Phase I study of tirapazamine plus cisplatin/etoposide and concurrent thoracic radiotherapy in limited-stage small cell lung cancer (S0004) A Southwest Oncology Group study Clin Cancer Res 10 2004 5418 5424
-
(2004)
Clin Cancer Res
, vol.10
, pp. 5418-5424
-
-
Le, Q.T.1
McCoy, J.2
Williamson, S.3
-
27
-
-
0002276619
-
Reductive metabolism: Its application to prodrug activation
-
N.J. Gooderham IOS Press Amsterdam
-
L.H. Patterson, S.M. Raleigh Reductive metabolism Its application to prodrug activation N.J. Gooderham Drug metabolism Towards the next millennium 1998 IOS Press Amsterdam 72 79
-
(1998)
Drug Metabolism: Towards the Next Millennium
, pp. 72-79
-
-
Patterson, L.H.1
Raleigh, S.M.2
-
28
-
-
0027220811
-
Rationale for the use of aliphatic N-oxides of cytotoxic anthraquinones as prodrug DNA binding agents: A new class of bioreductive agent
-
L.H. Patterson Rationale for the use of aliphatic N-oxides of cytotoxic anthraquinones as prodrug DNA binding agents A new class of bioreductive agent Cancer Metastasis Rev 12 1993 119 134
-
(1993)
Cancer Metastasis Rev
, vol.12
, pp. 119-134
-
-
Patterson, L.H.1
-
29
-
-
0034543132
-
AQ4N: A new approach to hypoxia-activated cancer chemotherapy
-
L.H. Patterson, S.R. McKeown AQ4N A new approach to hypoxia-activated cancer chemotherapy Br J Cancer 83 2000 1589 1593
-
(2000)
Br J Cancer
, vol.83
, pp. 1589-1593
-
-
Patterson, L.H.1
McKeown, S.R.2
-
30
-
-
0031040944
-
DNA topoisomerase II-dependent cytotoxicity to alkylaminoanthraquinones and their N-oxides
-
P.J. Smith, R. Desnoyers, N. Blunt DNA topoisomerase II-dependent cytotoxicity to alkylaminoanthraquinones and their N-oxides Cancer Chemother Pharmacol 39 1997 455 461
-
(1997)
Cancer Chemother Pharmacol
, vol.39
, pp. 455-461
-
-
Smith, P.J.1
Desnoyers, R.2
Blunt, N.3
-
31
-
-
0036041236
-
Bioreductively activated antitumor N-oxides: The case of AQ4N, a unique approach to hypoxia-activated cancer chemotherapy
-
L.H. Patterson Bioreductively activated antitumor N-oxides The case of AQ4N, a unique approach to hypoxia-activated cancer chemotherapy Drug Metab Rev 34 2002 581 592
-
(2002)
Drug Metab Rev
, vol.34
, pp. 581-592
-
-
Patterson, L.H.1
-
32
-
-
0029885455
-
Evidence for a therapeutic gain when AQ4N or tirapazamine is combined with radiation
-
S.R. McKeown, O.P. Friery, I.A. McIntyre Evidence for a therapeutic gain when AQ4N or tirapazamine is combined with radiation Br J Cancer Suppl 27 1996 S39 S42
-
(1996)
Br J Cancer
, Issue.27 SUPPL.
-
-
McKeown, S.R.1
Friery, O.P.2
McIntyre, I.A.3
-
33
-
-
0030022191
-
DNA damage following combination of radiation with the bioreductive drug AQ4N: Possible selective toxicity to oxic and hypoxic cells
-
M.V. Hejmadi, S.R. McKeown, O.P. Friery DNA damage following combination of radiation with the bioreductive drug AQ4N Possible selective toxicity to oxic and hypoxic cells Br J Cancer 73 1996 499 505
-
(1996)
Br J Cancer
, vol.73
, pp. 499-505
-
-
Hejmadi, M.V.1
McKeown, S.R.2
Friery, O.P.3
-
34
-
-
0029054994
-
AQ4N: An alkylaminoanthraquinon N-oxide showing bioreductive potential and positive interaction with radiation in vivo
-
S.R. McKeown, M.V. Hejmadi, I.A. McIntyre AQ4N An alkylaminoanthraquinon N-oxide showing bioreductive potential and positive interaction with radiation in vivo Br J Cancer 72 1995 76 81
-
(1995)
Br J Cancer
, vol.72
, pp. 76-81
-
-
McKeown, S.R.1
Hejmadi, M.V.2
McIntyre, I.A.3
-
35
-
-
30544434300
-
-
Web page title: Banoxantrone.
-
KuDOS Pharmaceutical, Inc. Available at: http://www.kudospharma.co.uk/ r_d/banox.php. Web page title: Banoxantrone. Accessed December 1, 2005.
-
-
-
-
36
-
-
0038149435
-
RSR13 plus cranial radiation therapy in patients with brain metastases: Comparison with the Radiation Therapy Oncology Group Recursive Partitioning Analysis Brain Metastases Database
-
E. Shaw, C. Scott, J. Suh RSR13 plus cranial radiation therapy in patients with brain metastases Comparison with the Radiation Therapy Oncology Group Recursive Partitioning Analysis Brain Metastases Database J Clin Oncol 21 2003 2364 2371
-
(2003)
J Clin Oncol
, vol.21
, pp. 2364-2371
-
-
Shaw, E.1
Scott, C.2
Suh, J.3
-
37
-
-
0035120517
-
Allosteric modification of oxygen delivery by hemoglobin
-
J. Whar, M. Gerber, J. Venitz Allosteric modification of oxygen delivery by hemoglobin Anesth Analg 92 2001 615 620
-
(2001)
Anesth Analg
, vol.92
, pp. 615-620
-
-
Whar, J.1
Gerber, M.2
Venitz, J.3
-
38
-
-
30544443379
-
Allosteric modifiers of hemoglobin: 2-[4-[[(3,5-disubstituted aniline) carbonyl]-methyl]phenoxyl]-2-methylproprionic acid derivatives that lower the oxygen affinity decreasing agents
-
D.J. Abraham, F.C. Wireko, R.S. Randad Allosteric modifiers of hemoglobin 2-[4-[[(3,5-disubstituted aniline) carbonyl]-methyl]phenoxyl]-2- methylproprionic acid derivatives that lower the oxygen affinity decreasing agents J Med Chem 34 1991 752 757
-
(1991)
J Med Chem
, vol.34
, pp. 752-757
-
-
Abraham, D.J.1
Wireko, F.C.2
Randad, R.S.3
-
39
-
-
0031737678
-
RSR13, a synthetic allosteric modifier of hemoglobin, as an adjunct to radiotherapy: Preliminary studies with EMT6 cells and tumors and normal tissues in mice
-
S. Rockwell, M. Kelley RSR13, a synthetic allosteric modifier of hemoglobin, as an adjunct to radiotherapy Preliminary studies with EMT6 cells and tumors and normal tissues in mice Radiat Oncol Invest 6 1998 199 208
-
(1998)
Radiat Oncol Invest
, vol.6
, pp. 199-208
-
-
Rockwell, S.1
Kelley, M.2
-
40
-
-
0029770717
-
RSR13: Effects on tumor oxygenation and response to therapy
-
B.A. Teicher, A. Gulshan, Y. Emi RSR13 Effects on tumor oxygenation and response to therapy Drug Dev Res 38 1996 1 11
-
(1996)
Drug Dev Res
, vol.38
, pp. 1-11
-
-
Teicher, B.A.1
Gulshan, A.2
Emi, Y.3
-
41
-
-
0029741416
-
Increased radiation response of FSaII fibrosarcoma in C3H mice following administration of an allosteric effector of hemoglobin-oxygen affinity
-
S.R. Khandelwal, P.-S. Lin, C.E. Hall Increased radiation response of FSaII fibrosarcoma in C3H mice following administration of an allosteric effector of hemoglobin-oxygen affinity Radiat Oncol Invest 4 1996 51059
-
(1996)
Radiat Oncol Invest
, vol.4
, pp. 51059
-
-
Khandelwal, S.R.1
Lin, P.-S.2
Hall, C.E.3
-
42
-
-
4043097165
-
Standard whole brain radiation therapy (WBRT) with supplemental oxygen with or without RSR13 (Efaproxiral) in patients with brain metastases: Results of the randomized REACH (RT-009) Study
-
J. Suh, B. Stea, J. Nabid Standard whole brain radiation therapy (WBRT) with supplemental oxygen with or without RSR13 (Efaproxiral) in patients with brain metastases Results of the randomized REACH (RT-009) Study [Abstract] J Clin Oncol 22 2004 1534
-
(2004)
J Clin Oncol
, vol.22
, pp. 1534
-
-
Suh, J.1
Stea, B.2
Nabid, J.3
-
44
-
-
0032796232
-
Phase I trial to determine the safety, pharmacodynamics, and pharmacokinetics of RSR13, a novel radioenhancer, in newly diagnosed glioblastoma multiforme
-
L. Kleinberg, S.A. Grossman, S. Piantadosi Phase I trial to determine the safety, pharmacodynamics, and pharmacokinetics of RSR13, a novel radioenhancer, in newly diagnosed glioblastoma multiforme J Clin Oncol 17 1999 2593 2603
-
(1999)
J Clin Oncol
, vol.17
, pp. 2593-2603
-
-
Kleinberg, L.1
Grossman, S.A.2
Piantadosi, S.3
-
45
-
-
0037099687
-
Survival of patients with newly diagnosed glioblastoma multiforme treated with RSR13 and radiotherapy: Results of a phase II new approaches to brain tumor therapy CNS Consortium Safety and Efficacy Study
-
L. Kleinberg, S.A. Grossman, K. Carson Survival of patients with newly diagnosed glioblastoma multiforme treated with RSR13 and radiotherapy Results of a phase II new approaches to brain tumor therapy CNS Consortium Safety and Efficacy Study J Clin Oncol 20 2002 3149 3155
-
(2002)
J Clin Oncol
, vol.20
, pp. 3149-3155
-
-
Kleinberg, L.1
Grossman, S.A.2
Carson, K.3
-
46
-
-
33644583036
-
Primary and metastatic tumors of the nervous system
-
D.L. Kasper A.S. Fauci D.L. Longo E. Braunwald S.L. Hauser J.L. Jameson McGraw Hill Companies, Inc New York
-
S.M. Sagar, M.A. Israel Primary and metastatic tumors of the nervous system D.L. Kasper A.S. Fauci D.L. Longo E. Braunwald S.L. Hauser J.L. Jameson Harrison's principles of internal medicine 2005 McGraw Hill Companies, Inc New York 2453
-
(2005)
Harrison's Principles of Internal Medicine
, pp. 2453
-
-
Sagar, S.M.1
Israel, M.A.2
-
47
-
-
33746877799
-
Evaluation of safety and tolerance of escalating doses of RSR13 administered with a fixed dose of BCNU every 6 weeks in patients with recurrent malignant glioma: Results of the phase I NABTT 9806 clinical trial
-
P.Z. New, S. Grossman, T. Mikkelsen Evaluation of safety and tolerance of escalating doses of RSR13 administered with a fixed dose of BCNU every 6 weeks in patients with recurrent malignant glioma Results of the phase I NABTT 9806 clinical trial [Abstract] J Clin Oncol 22 2004 1533
-
(2004)
J Clin Oncol
, vol.22
, pp. 1533
-
-
New, P.Z.1
Grossman, S.2
Mikkelsen, T.3
-
48
-
-
30544442529
-
Safety profile of efaproxiral (RSR13), a novel radiation sensitizer, in patients undergoing radiation therapy
-
B. Stea, A. Nabid, J. Kresl Safety profile of efaproxiral (RSR13), a novel radiation sensitizer, in patients undergoing radiation therapy [Abstract] J Clin Oncol 22 2004 3090
-
(2004)
J Clin Oncol
, vol.22
, pp. 3090
-
-
Stea, B.1
Nabid, A.2
Kresl, J.3
-
49
-
-
0242336439
-
Pharmacokinetics of escalating IV doses of an allosteric hemoglobin modifier (RSR13) in healthy volunteers
-
J. Venitz, P.W. Slattum, M. Gerber Pharmacokinetics of escalating IV doses of an allosteric hemoglobin modifier (RSR13) in healthy volunteers [Abstract] Pharm Res 13 1996 s479
-
(1996)
Pharm Res
, vol.13
, pp. 479
-
-
Venitz, J.1
Slattum, P.W.2
Gerber, M.3
-
50
-
-
0035889348
-
Redox cycling by motexafin gadolinium enhances cellular response to ionizing radiation by forming reactive oxygen species
-
D. Magda, C. Lepp, G. Nokolay Redox cycling by motexafin gadolinium enhances cellular response to ionizing radiation by forming reactive oxygen species Int J Radiation Oncology Biol Phys 51 2001 1025 1036
-
(2001)
Int J Radiation Oncology Biol Phys
, vol.51
, pp. 1025-1036
-
-
Magda, D.1
Lepp, C.2
Nokolay, G.3
-
51
-
-
0034797931
-
Motexafin gadolinium: A redox active drug that enhances the efficacy of bleomycin and doxorubicin
-
R. Miller, K. Woodburn, Q. Fan Motexafin gadolinium A redox active drug that enhances the efficacy of bleomycin and doxorubicin Clinical Cancer Research 7 2001 3215 3221
-
(2001)
Clinical Cancer Research
, vol.7
, pp. 3215-3221
-
-
Miller, R.1
Woodburn, K.2
Fan, Q.3
-
52
-
-
0032747288
-
In vivo animal studies with gadolinium (III) texaphyrin as a radiation enhancer
-
R. Miller, K. Woodburn, Q. Fan In vivo animal studies with gadolinium (III) texaphyrin as a radiation enhancer Int J Radiat Oncol Biol Phys 45 1999 981 989
-
(1999)
Int J Radiat Oncol Biol Phys
, vol.45
, pp. 981-989
-
-
Miller, R.1
Woodburn, K.2
Fan, Q.3
-
53
-
-
0032874534
-
Phases IB and II multidose trial of gadolinium texaphyrin, a radiation sensitizer detectable at MR imaging: Preliminary results in brain metastases
-
J. Viala, D. Vanel, P. Meingan Phases IB and II multidose trial of gadolinium texaphyrin, a radiation sensitizer detectable at MR imaging Preliminary results in brain metastases Radiology 212 1999 755 759
-
(1999)
Radiology
, vol.212
, pp. 755-759
-
-
Viala, J.1
Vanel, D.2
Meingan, P.3
-
54
-
-
1042281012
-
Motexafin gadolinium
-
Motexafin gadolinium Drugs R & D 5 2004 52 57
-
(2004)
Drugs R & D
, vol.5
, pp. 52-57
-
-
-
55
-
-
0035312794
-
Effects of motexafin gadolinium on tumor metabolism and radiation sensitivity
-
S. Xu, K. Zakian, H. Thaler Effects of motexafin gadolinium on tumor metabolism and radiation sensitivity Int J Radiat Oncol Biol Phys 49 2001 1381 1390
-
(2001)
Int J Radiat Oncol Biol Phys
, vol.49
, pp. 1381-1390
-
-
Xu, S.1
Zakian, K.2
Thaler, H.3
-
56
-
-
0037133332
-
Motexafin gadolinium (Gd-Tex) selectively induces apoptosis in HIV-1 infected CD4+ T helper cells
-
O. Perez, G. Nolan, D. Magda Motexafin gadolinium (Gd-Tex) selectively induces apoptosis in HIV-1 infected CD4+ T helper cells Proc Natl Acad Sci 99 2002 2270 2274
-
(2002)
Proc Natl Acad Sci
, vol.99
, pp. 2270-2274
-
-
Perez, O.1
Nolan, G.2
Magda, D.3
-
57
-
-
0025244976
-
Changes in radiation sensitization induced by Fluosol-DA as measured by 31-P NMR
-
J.A. Koutcher, A.A. Alfieri, M.L. Devitt Changes in radiation sensitization induced by Fluosol-DA as measured by 31-P NMR Cancer Res 50 1990 7252 7256
-
(1990)
Cancer Res
, vol.50
, pp. 7252-7256
-
-
Koutcher, J.A.1
Alfieri, A.A.2
Devitt, M.L.3
-
58
-
-
1842424239
-
Effects of texaphyrins on the oxygenation of EMT6 mouse mammary tumors
-
E.T. Donnelly, Y. Liu, Y.O. Fatunmbi Effects of texaphyrins on the oxygenation of EMT6 mouse mammary tumors Int J Radiat Oncol Biol Phys 58 2004 1570 1576
-
(2004)
Int J Radiat Oncol Biol Phys
, vol.58
, pp. 1570-1576
-
-
Donnelly, E.T.1
Liu, Y.2
Fatunmbi, Y.O.3
-
60
-
-
0030013113
-
Gadolinium (III) texaphyrin: A tumor selective radiation sensitizer that is detectable by MRI
-
S.W. Young, F. Qing, A. Harriman Gadolinium (III) texaphyrin A tumor selective radiation sensitizer that is detectable by MRI Proc Natl Acad Sci U S A 93 1996 6610 6615
-
(1996)
Proc Natl Acad Sci U S a
, vol.93
, pp. 6610-6615
-
-
Young, S.W.1
Qing, F.2
Harriman, A.3
-
61
-
-
0033958684
-
Re-evaluating gadolinium (III) texaphyrin as a radiosensitizing agent
-
E.J. Bernhard, J.B. Mitchel, D. Deen Re-evaluating gadolinium (III) texaphyrin as a radiosensitizing agent Cancer Res 60 2000 86 91
-
(2000)
Cancer Res
, vol.60
, pp. 86-91
-
-
Bernhard, E.J.1
Mitchel, J.B.2
Deen, D.3
-
62
-
-
0036804365
-
Preliminary studies of the effects of gadolinium texaphyrin on the growth and radiosensitivity of EMT6 cells in vitro
-
S. Rockwell, E. Donnelly, L. Yanfeng Preliminary studies of the effects of gadolinium texaphyrin on the growth and radiosensitivity of EMT6 cells in vitro Int J Radiat Oncol Biol Phys 54 2002 536 541
-
(2002)
Int J Radiat Oncol Biol Phys
, vol.54
, pp. 536-541
-
-
Rockwell, S.1
Donnelly, E.2
Yanfeng, L.3
-
63
-
-
0037676125
-
Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole brain radiation therapy in brain metastases
-
M. Mehta, P. Rodrigus, C.H.J. Terhaard Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole brain radiation therapy in brain metastases J Clin Oncol 21 2003 2529 2536
-
(2003)
J Clin Oncol
, vol.21
, pp. 2529-2536
-
-
Mehta, M.1
Rodrigus, P.2
Terhaard, C.H.J.3
-
64
-
-
3042787102
-
Neurocognitive function and progression in patients with brain metastases treated with whole brain radiation and motexafin gadolinium: Results of a randomized phase III trial
-
C. Meyers, J. Smith, A. Bezjak Neurocognitive function and progression in patients with brain metastases treated with whole brain radiation and motexafin gadolinium Results of a randomized phase III trial J Clin Oncol 22 2004 157-156
-
(2004)
J Clin Oncol
, vol.22
-
-
Meyers, C.1
Smith, J.2
Bezjak, A.3
-
65
-
-
0034443675
-
Reversible renal toxicity resulting from high single doses of the new radiosensitizer, gadolinium texaphyrin
-
D. Rosenthal, C. Becerra, R. Toto Reversible renal toxicity resulting from high single doses of the new radiosensitizer, gadolinium texaphyrin Am J Clin Oncol (CCT) 23 2000 593 598
-
(2000)
Am J Clin Oncol (CCT)
, vol.23
, pp. 593-598
-
-
Rosenthal, D.1
Becerra, C.2
Toto, R.3
-
66
-
-
0035300617
-
Multicenter phase Ib/II trial of the radiation sensitizer motexafin gadolinium in patients with brain metastases
-
P. Carde, R. Timmerman, M. Mehta Multicenter phase Ib/II trial of the radiation sensitizer motexafin gadolinium in patients with brain metastases J Clin Oncol 19 2001 2074 2083
-
(2001)
J Clin Oncol
, vol.19
, pp. 2074-2083
-
-
Carde, P.1
Timmerman, R.2
Mehta, M.3
-
69
-
-
10644260910
-
Comparison of survival of patients in the phase I study of motexafin gadolinium with radiation therapy for glioblastoma multiforme, with a matched cohort of patients from the RTOG RPA database
-
J.M. Ford, W. Seiferheld, M. Mehta Comparison of survival of patients in the phase I study of motexafin gadolinium with radiation therapy for glioblastoma multiforme, with a matched cohort of patients from the RTOG RPA database [Abstract] Proc Am Soc Clin Oncol 22 2003 106
-
(2003)
Proc Am Soc Clin Oncol
, vol.22
, pp. 106
-
-
Ford, J.M.1
Seiferheld, W.2
Mehta, M.3
-
70
-
-
30544451624
-
-
J. Suh, E. Chang, R. Timmerman Phase II trial of motefaxin gadolinium (MGd, Xcytrin®) and cranial radiation in newly diagnosed glioblastoma multiforme (GBM) 2002 [Abstract]. 2002 ASCO annual meeting, May 18-21, Orlando, FL
-
(2002)
Phase II Trial of Motefaxin Gadolinium (MGd, Xcytrin®) and Cranial Radiation in Newly Diagnosed Glioblastoma Multiforme (GBM)
-
-
Suh, J.1
Chang, E.2
Timmerman, R.3
-
74
-
-
0032493368
-
Regulation of hypoxia-inducible factor 1 alpha is mediated by an O2 dependent degradation domain via the ubiquitin-proteasome pathway
-
L.E. Huang, J. Gu, M. Schau Regulation of hypoxia-inducible factor 1 alpha is mediated by an O2 dependent degradation domain via the ubiquitin-proteasome pathway Proc Natl Acad Sci U S A 95 1998 7987 7992
-
(1998)
Proc Natl Acad Sci U S a
, vol.95
, pp. 7987-7992
-
-
Huang, L.E.1
Gu, J.2
Schau, M.3
-
75
-
-
0030961006
-
Hypoxia-inducible factor 1 alpha protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes
-
S. Salceda, J. Caro Hypoxia-inducible factor 1 alpha protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes J Biol Chem 272 1997 22642 22647
-
(1997)
J Biol Chem
, vol.272
, pp. 22642-22647
-
-
Salceda, S.1
Caro, J.2
-
76
-
-
0035012605
-
HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1 alpha synthesis: Novel mechanism for HIF-1 mediated vascular endothelial growth factor expression
-
E. Laughner, P. Taghavi, K. Chiles HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1 alpha synthesis Novel mechanism for HIF-1 mediated vascular endothelial growth factor expression Mol Cell Biol 21 2001 3995 4004
-
(2001)
Mol Cell Biol
, vol.21
, pp. 3995-4004
-
-
Laughner, E.1
Taghavi, P.2
Chiles, K.3
-
77
-
-
0037131271
-
Role of prolyl hydroxylation in oncogenically stabilized hypoxia-inducible factor-1 alpha
-
D.A. Chan, P.D. Sutphin, N.D. Denko Role of prolyl hydroxylation in oncogenically stabilized hypoxia-inducible factor-1 alpha J Biol Chem 277 2002 40112 40117
-
(2002)
J Biol Chem
, vol.277
, pp. 40112-40117
-
-
Chan, D.A.1
Sutphin, P.D.2
Denko, N.D.3
-
78
-
-
0035003528
-
Gene transfer of antisense hypoxia inducible factor-1 alpha enhances the therapeutic efficacy of cancer immunotherapy
-
X. Sun, J.R. Kanwar, E. Leung Gene transfer of antisense hypoxia inducible factor-1 alpha enhances the therapeutic efficacy of cancer immunotherapy Gene Ther 8 2001 638 645
-
(2001)
Gene Ther
, vol.8
, pp. 638-645
-
-
Sun, X.1
Kanwar, J.R.2
Leung, E.3
-
79
-
-
0037083845
-
A dominant-negative isoform lacking exons 11 and 12 of the human hypoxia-inducible factor-1 alpha gene
-
Y.S. Chun, E. Choi, T.Y. Kim A dominant-negative isoform lacking exons 11 and 12 of the human hypoxia-inducible factor-1 alpha gene Biochem J 362 2002 71 79
-
(2002)
Biochem J
, vol.362
, pp. 71-79
-
-
Chun, Y.S.1
Choi, E.2
Kim, T.Y.3
-
80
-
-
0032749463
-
Hypoxia-induced activation of HIF-1: Role of HIF-1 alpha-HSP90 interaction
-
E. Minet, D. Mottet, G. Michel Hypoxia-induced activation of HIF-1 Role of HIF-1 alpha-HSP90 interaction FEBS Lett 460 1999 251 256
-
(1999)
FEBS Lett
, vol.460
, pp. 251-256
-
-
Minet, E.1
Mottet, D.2
Michel, G.3
-
81
-
-
0037119415
-
HSP90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alpha degradative pathway
-
J.S. Isaacs, Y.J. Jung, E.G. Mimnaugh HSP90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alpha degradative pathway J Biol Chem 277 2002 29936 29944
-
(2002)
J Biol Chem
, vol.277
, pp. 29936-29944
-
-
Isaacs, J.S.1
Jung, Y.J.2
Mimnaugh, E.G.3
-
82
-
-
0034654174
-
Modulation of hypoxia-inducible factor 1 alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: Implications for tumor angiogenesis and therapeutics
-
H. Zhong, K. Chiles, D. Feldser Modulation of hypoxia-inducible factor 1 alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells Implications for tumor angiogenesis and therapeutics Cancer Res 60 2000 1541 1545
-
(2000)
Cancer Res
, vol.60
, pp. 1541-1545
-
-
Zhong, H.1
Chiles, K.2
Feldser, D.3
-
83
-
-
0037008770
-
Insulin stimulates hypoxia-inducible factor 1 through a phosphatidylinositol 3-kinase/target of rapamycin-dependent signaling pathway
-
C. Treins, S. Giorgetti-Peraldi, J. Murdaca Insulin stimulates hypoxia-inducible factor 1 through a phosphatidylinositol 3-kinase/target of rapamycin-dependent signaling pathway Biol Chem 277 2002 27975 27981
-
(2002)
Biol Chem
, vol.277
, pp. 27975-27981
-
-
Treins, C.1
Giorgetti-Peraldi, S.2
Murdaca, J.3
-
84
-
-
0035871942
-
Inhibitory effect of YC-1 on the hypoxic induction of erythropoietin and vascular endothelial growth factor in Hep3B cells
-
Y.S. Chun, E.J. Yeo, E. Choi Inhibitory effect of YC-1 on the hypoxic induction of erythropoietin and vascular endothelial growth factor in Hep3B cells Biochem Pharmacol 61 2001 947 954
-
(2001)
Biochem Pharmacol
, vol.61
, pp. 947-954
-
-
Chun, Y.S.1
Yeo, E.J.2
Choi, E.3
-
85
-
-
0037414180
-
YC-1: A potential anticancer drug targeting hypoxia-inducible factor 1
-
E.J. Eo, Y.S. Chun, Y.S. Cho YC-1 A potential anticancer drug targeting hypoxia-inducible factor 1 J Natl Cancer Inst 95 2003 516 525
-
(2003)
J Natl Cancer Inst
, vol.95
, pp. 516-525
-
-
Eo, E.J.1
Chun, Y.S.2
Cho, Y.S.3
-
86
-
-
0036569704
-
Geldanamycin induces degradation of hypoxia-inducible factor 1 alpha protein via the proteosome pathway in prostate cancer cells
-
N.J. Mabjeesh, D.E. Post, M.T. Willard Geldanamycin induces degradation of hypoxia-inducible factor 1 alpha protein via the proteosome pathway in prostate cancer cells Cancer Res 62 2002 2478 2482
-
(2002)
Cancer Res
, vol.62
, pp. 2478-2482
-
-
Mabjeesh, N.J.1
Post, D.E.2
Willard, M.T.3
-
87
-
-
30544441465
-
Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells
-
R. Fukuda, K. Hirota, F. Fan Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells J Biol Chem 512 2002 157 162
-
(2002)
J Biol Chem
, vol.512
, pp. 157-162
-
-
Fukuda, R.1
Hirota, K.2
Fan, F.3
-
88
-
-
0037070223
-
Normoxic induction of the hypoxia inducible factor 1 alpha by insulin and interleukin 1 beta involves the phsphatidylinositol 3-kinase pathway
-
D.P. Stiehl, W. Jelkmann, R.H. Wenger Normoxic induction of the hypoxia inducible factor 1 alpha by insulin and interleukin 1 beta involves the phsphatidylinositol 3-kinase pathway FEBS Lett 512 2002 157 162
-
(2002)
FEBS Lett
, vol.512
, pp. 157-162
-
-
Stiehl, D.P.1
Jelkmann, W.2
Wenger, R.H.3
-
89
-
-
0036682284
-
Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway
-
A. Rapisarda, B. Uranchimeg, D.A. Scudiero Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway Cancer Res 62 2002 4316 4324
-
(2002)
Cancer Res
, vol.62
, pp. 4316-4324
-
-
Rapisarda, A.1
Uranchimeg, B.2
Scudiero, D.A.3
-
90
-
-
0037500967
-
Overexpression of hypoxia-inducible factor 1 alpha indicates diminished response to radiotherapy and unfavorable prognosis in patients receiving radiotherapy for cervical cancer
-
B. Bachtiary, M. Schindl, R. Potter Overexpression of hypoxia-inducible factor 1 alpha indicates diminished response to radiotherapy and unfavorable prognosis in patients receiving radiotherapy for cervical cancer Clin Can Res 9 2003 2234 2240
-
(2003)
Clin Can Res
, vol.9
, pp. 2234-2240
-
-
Bachtiary, B.1
Schindl, M.2
Potter, R.3
-
91
-
-
20944449117
-
Enhanced response to radiotherapy in tumours deficient in the function of hypoxia-inducible factor 1
-
K.J. Williams, B.A. Telfer, D. Xenaki Enhanced response to radiotherapy in tumours deficient in the function of hypoxia-inducible factor 1 Radiother Oncol 75 2005 89 98
-
(2005)
Radiother Oncol
, vol.75
, pp. 89-98
-
-
Williams, K.J.1
Telfer, B.A.2
Xenaki, D.3
-
92
-
-
2342611976
-
Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: Role of reoxygenation, free radicals, and stress granules
-
B.J. Moeller, Y. Cao, C.Y. Li Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors Role of reoxygenation, free radicals, and stress granules Cancer Cell 5 2004 429 441
-
(2004)
Cancer Cell
, vol.5
, pp. 429-441
-
-
Moeller, B.J.1
Cao, Y.2
Li, C.Y.3
-
93
-
-
23644453277
-
Pleiotropic effects of HIF-1 blockade on tumor radiosensitivity
-
B.J. Moeller, M.R. Dreher, Z.N. Rabbani Pleiotropic effects of HIF-1 blockade on tumor radiosensitivity Cancer Cell 8 2005 99 110
-
(2005)
Cancer Cell
, vol.8
, pp. 99-110
-
-
Moeller, B.J.1
Dreher, M.R.2
Rabbani, Z.N.3
-
94
-
-
30544432610
-
Enhancement of antitumor activity of the anti-EGF receptor monoclonal antibody cetuximab/C335 by perifosine in PTEN-deficient cancer cells
-
X. Li, R. Luwor, Y. Lu Enhancement of antitumor activity of the anti-EGF receptor monoclonal antibody cetuximab/C335 by perifosine in PTEN-deficient cancer cells Oncogene 2005 Sep 19; [Epub ahead of print]
-
(2005)
Oncogene
-
-
Li, X.1
Luwor, R.2
Lu, Y.3
|